Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH03 Saxagliptin
D10262 Saxagliptin hydrochloride <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin
D10262 Saxagliptin hydrochloride
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
DG00119 Saxagliptin
D10262 Saxagliptin hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00119 Saxagliptin
D10262 Saxagliptin hydrochloride
DG02925 CYP3A5 substrate
DG00119 Saxagliptin
D10262 Saxagliptin hydrochloride
Drug classes [BR:br08332]
Antidiabetic agent
DG01601 DPP-4 inhibitor
D10262 Saxagliptin hydrochloride
DG02044 Hypoglycemic agent
D10262 Saxagliptin hydrochloride
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Prolyl oligopeptidase family
DPP4 (CD26)
D10262 Saxagliptin hydrochloride <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10262
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10262
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10262
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10262
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
DG00119 Saxagliptin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00119 Saxagliptin
DG02925 CYP3A5 substrate
DG00119 Saxagliptin